Compare Novavax Inc (NVAX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs PepsiCo, Inc. — how do they compare? Novavax Inc trades at $7.89 (market cap $1.31B), while PepsiCo, Inc. trades at $137.77 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 144.2× Novavax Inc's market cap, and PepsiCo, Inc. pays a 4.28% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PEP | |
|---|---|---|
Market Cap | $1.31B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $11.19 | $170.44 |
52-Week Low | $6.22 | $134.95 |
Enterprise Value | $889.30M | $231.41B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong fundamentals with $93.93B revenue in 2025, 10.78% net margin, and consistent dividend payments. Recent news highlights price adjustments for snack products and sponsorship withdrawals, while analysts project 15% upside to the $158.79 consensus target.
PepsiCo presents a mixed outlook with solid fundamentals and dividend yield offset by near-term price pressure and competitive challenges. The stock offers value at current levels for income investors, though execution risks in North America and consumer pricing sensitivity require monitoring. Wall Street maintains cautious optimism with 64% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
